Shots:

• The two P-III study BREEZE-AD1 and BREEZE-AD2 involves assessing of baricitinib vs PBO in patients with moderate-to-severe AD
• The two P-III study resulted in meeting 1EPs @16 wks. with no venous thromboembolic events (VTEs)- major adverse cardiovascular events (MACE) & deaths rates
• Olumiant (baricitinib- 2mg) indicated for moderate-to-severe RA who have had an inadequate response to TNF antagonist therapies and is approved in 50 countries including the US- EU- and Japan. In Dec-2009 Lilly and Incyte collaborated to develop and commercialize baricitinib for inflammatory and autoimmune diseases

   Ref: PRNewswire | Image: Eli Lilly